Steroids were not controlling Greg’s ulcerative colitis, so his gastroenterologist put him on a biologic medication. After a while, his insurance plan recommended switching to a biosimilar—a safe, effective alternative to a brand-name biologic. “My doctor was on board,” recalls Greg, a weight lifter and pizza fanatic. “I trust my doctor, so I switched to the biosimilar and it’s been smooth sailing ever since.”
Savings from biosimilars for patients like Greg totaled $8 billion in 2020 and are projected to save $133 billion over the next five years.
Video
Issues